Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Real world data on primary treatment for mantle cell lymphoma: a Nordic Lymphoma Group observational study

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Clonal hematopoiesis in elderly twins: concordance, discordance and mortality

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Skin colonization by circulating neoplastic clones in cutaneous T-cell lymphoma

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Low vs. high hemoglobin trigger for Transfusion in Vascular surgery (TV): a randomized clinical feasibility trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. The preleukemic TCF3-PBX1 gene fusion can be generated in utero and is present in ≈0.6% of healthy newborns

    Research output: Contribution to journalLetterResearchpeer-review

  1. No association between early maternal HbA1c and offspring birthweight among women without pre-existing diabetes in Greenland

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Increased risk of anemia, neutropenia and thrombocytopenia in people with HIV and well-controlled viral replication

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Blodsygdomme

    Research output: Chapter in Book/Report/Conference proceedingBook chapterCommunication

View graph of relations

There is consensus that young patients with mantle cell lymphoma (MCL) should receive intensive immunochemotherapy regimens, but optimal treatment of elderly patients as well for as patients with limited or indolent disease is not defined. Our aim was to evaluate and compare outcome in relation to prognostic factors and first-line treatment in patients with MCL in a population-based data set. Data were collected from the Swedish and Danish Lymphoma Registries from the period of 2000 to 2011. A total of 1389 patients were diagnosed with MCL. During this period, age-standardized incidence MCL increased, most prominently among males. Furthermore, male gender was associated with inferior overall survival (OS) in multivariate analysis (hazard ratio [HR] = 1.36; P = .002). Forty-three (3.6%) patients with stage I-II disease received radiotherapy with curative intent, showing a 3-year OS of 93%. Twenty-nine (2.4%) patients followed a watch-and-wait approach and showed a 3-year OS of 79.8%. Among patients receiving systemic treatment, rituximab (n = 766; HR = 0.66; P = .001) and autologous stem cell transplant (n = 273; HR = 0.55; P = .004) were independently associated with improved OS in multivariate analysis. Hence, by a population-based approach, we were able to provide novel data on prognostic factors and primary treatment of MCL, applicable to routine clinical practice.

Original languageEnglish
JournalBlood
Volume124
Issue number8
Pages (from-to)1288-95
Number of pages8
ISSN0006-4971
DOIs
Publication statusPublished - 21 Aug 2014

    Research areas

  • Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Murine-Derived, Antineoplastic Agents, Autografts, Disease-Free Survival, Female, Humans, Incidence, Lymphoma, Mantle-Cell, Male, Middle Aged, Neoplasm Staging, Radiotherapy, Registries, Retrospective Studies, Sex Factors, Stem Cell Transplantation, Survival Rate

ID: 44646729